Javascript must be enabled to continue!
HIF1α reinforces PPARγ-dependent metabolic rechanneling to support lipid accumulation in adipocytes
View through CrossRef
Introduction
Adipose tissue hypoxia is a hallmark of obesity and partly contributes to metabolic dysfunction through effects on differentiated adipocytes. Although hypoxia-inducible factor 1α (HIF1α) is a key transcriptional mediator of hypoxic responses, its state-dependent metabolic role remains incompletely defined in mature adipocytes. Herein, we investigate how HIF1α regulates lipid metabolism in differentiated adipocytes under nutrient excess conditions.
Methods
An adipocyte-specific Hif1α knockout mouse model was subjected to high-fat diet feeding
in vivo
. Adipose mass, adipocyte size, glucose tolerance, and insulin sensitivity were assessed. Metabolic and enzymatic analyses focused on lipid anabolic pathways, including glycolysis-linked glycerolipid biosynthesis and PPARγ-dependent programs.
Results
Adipocyte-specific deletion of Hif1α attenuated adipocyte hypertrophy, resulting in reduced adipose mass as well as improved systemic glucose tolerance and insulin sensitivity during high-fat diet feeding. Mechanistically, HIF1α reinforced PPARγ-dependent lipid anabolic programs by coordinating glycolytic flux with glycerolipid biosynthesis to promote the rechanneling of glucose-derived intermediates into triacylglyceride synthesis.
Discussion
Together, these findings provide metabolic and enzymatic validations of a late-stage, state-dependent HIF1α–PPARγ lipid storage program and implicate the glycerol-3-phosphate dehydrogenase 1 (GPD1)–glycerol-3-phosphate acyltransferase (GPAT) axis as a key molecular executor of hypertrophic lipid accumulation in differentiated adipocytes.
Title: HIF1α reinforces PPARγ-dependent metabolic rechanneling to support lipid accumulation in adipocytes
Description:
Introduction
Adipose tissue hypoxia is a hallmark of obesity and partly contributes to metabolic dysfunction through effects on differentiated adipocytes.
Although hypoxia-inducible factor 1α (HIF1α) is a key transcriptional mediator of hypoxic responses, its state-dependent metabolic role remains incompletely defined in mature adipocytes.
Herein, we investigate how HIF1α regulates lipid metabolism in differentiated adipocytes under nutrient excess conditions.
Methods
An adipocyte-specific Hif1α knockout mouse model was subjected to high-fat diet feeding
in vivo
.
Adipose mass, adipocyte size, glucose tolerance, and insulin sensitivity were assessed.
Metabolic and enzymatic analyses focused on lipid anabolic pathways, including glycolysis-linked glycerolipid biosynthesis and PPARγ-dependent programs.
Results
Adipocyte-specific deletion of Hif1α attenuated adipocyte hypertrophy, resulting in reduced adipose mass as well as improved systemic glucose tolerance and insulin sensitivity during high-fat diet feeding.
Mechanistically, HIF1α reinforced PPARγ-dependent lipid anabolic programs by coordinating glycolytic flux with glycerolipid biosynthesis to promote the rechanneling of glucose-derived intermediates into triacylglyceride synthesis.
Discussion
Together, these findings provide metabolic and enzymatic validations of a late-stage, state-dependent HIF1α–PPARγ lipid storage program and implicate the glycerol-3-phosphate dehydrogenase 1 (GPD1)–glycerol-3-phosphate acyltransferase (GPAT) axis as a key molecular executor of hypertrophic lipid accumulation in differentiated adipocytes.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Abstract 462: Targeting hepatocellular carcinoma by suppressing HIF-1 alpha alone and in combination with therapeutic drugs
Abstract 462: Targeting hepatocellular carcinoma by suppressing HIF-1 alpha alone and in combination with therapeutic drugs
Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer related death. HIF-1 alpha (HIF1α) is ove...
Peroxisome proliferator‐activated receptor γ upregulates galectin‐9 and predicts prognosis in intestinal‐type gastric cancer
Peroxisome proliferator‐activated receptor γ upregulates galectin‐9 and predicts prognosis in intestinal‐type gastric cancer
The importance of PPARγ (peroxisome proliferator‐activated receptor γ) in gastric cancer (GC) is unclear. We investigated the role of PPARγ in GC cell lines and an animal model, an...
The Regulation of Hypoxia Inducible Factor (HIF)1α Expression by Quercetin: an In Silico Study
The Regulation of Hypoxia Inducible Factor (HIF)1α Expression by Quercetin: an In Silico Study
Background: Cancer disease is a growing health problem in developing and developed countries. Hypoxia-inducible factor-1a (HIF1α) is a transcription factor responsible for expressi...
Entwicklung von chemischen Tools für nukleäre Rezeptoren
Entwicklung von chemischen Tools für nukleäre Rezeptoren
Nukleäre Rezeptoren (NRs) sind ligandengesteuerte Transkriptionsfaktoren, die sich aus einer Superfamilie von 48 humanen Mitgliedern zusammensetzt. Seit vielen Jahrzehnten stellen ...

